In #TechBio news, a post on the definition of TechBio as found in the first Google search hit I found, followed by a possible alt definitions stemming from the comparison of the terms #techbio and #biotech Dx/Tx:
medium.com/cantos-venture…
Definition: "TechBio is the direct application of engineering to biology".
"[...] applying an engineering mindset to solving biological problems means we can still work with limited information. We see TechBio as being concerned with four main components:
1. Reading bio — understanding genetic information (DNA, RNA, proteins, etc.) ex: next-gen sequencing
2. Writing bio — synthesizing DNA, RNA, and protein constructs. ex: creating custom DNA oligonucleotides
3. Programming bio — manipulating genetic information or small molecules for therapeutic purposes. ex: designing complex antibody drugs to treat metastatic cancer
4. Delivering bio — routing biological information to the correct tissues and cells. ex: delivery of RNA drugs
One alternative definition of #techbio to differentiate to #biotech I pose here:
In Tech+Bio, without cutting edge "Tech", you don't obtain anything useful from the "Bio" part. So you apply the "Tech" to the "Bio" to obtain a product for Dx or Tx.
In Bio+Tech, you are harnessing or engineering the "Bio" part, and this may involve technology that has been around for decades, then turn that "engineered Bio" into a product for Dx or Tx.
Maybe stretching the alternative definition to a certain point, one could say that in "Tech+Bio" you need cutting edge tech and some Bio to turn into a product (Dx or Tx). The cutting edge tech may be the one USP you emphasize in your slide decks.
In "Bio+Tech", the "Bio" part may be the company USP, and it may be a biological entity or artifact that nobody else knows how to engineer/produce better than you. The "Tech" part may or may not be cutting edge, but would be less important than the biological entity.
I tweet very little about #TechBio, and track very few companies with any TechBio angle in their business plan, so I am only a distant witness of the comings and goings of TechBio on @twitter. I wouldn't put NGS (DNA reading) in the TechBio bucket...
... but I am happy to be convinced otherwise. I do follow other #biotech companies and fields, which you can learn more about on my Twitter feed @albertvilella and also at bit.ly/biotech-slides

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Albert Vilella

Albert Vilella Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertVilella

Sep 30
Illumina presented their new high-throughput instrument on Thursday, the NovaSeq X Plus, a a new mark of $200/WGS or $2/Gb in a machine capabale of producing 20,000 WGS per year. What are the implications for the field of NGS as a whole?
First of all, it's worth mentioning that 5 years after the release of the NovaSeq, with the first batch of NovaSeq X Plus instruments being delivered in customer's hands in Feb/March 2023, this release will coincide with both MGI Tech and Ultima Genomics starting to deliver
instrument in the $100-200/WGS or $1-2/Gb range with very similar CAPEX and throughput profiles to the new Illumina sequencer. This may be the first new Illumina instrument that will enter the market with the main specs of reagent cost / throughput / instrument cost not being
Read 36 tweets
Sep 29
Genomeweb asked about the price per Gb of the NextSeq P4 flowcell (2024) but $ILMN Illumina didn't give any details on pricing. So it's not $6/Gb. Based on the NovaSeq SP/S1/S2/S4 current pricing, the P4 would naturally slot in at a $12-15/Gb range, but who knows what it will...
... be in 2024. By then maybe the NovaSeq pricing itself has shrunk, e.g. to a $9/$8/$6/$4 range, then the P4 could be priced at the same price as the NovaSeq SP 2024 range at $9/Gb. All speculation at this point.
This is to say that the NextSeq 1000/2000 is not and may not be in 2024 a $6/Gb platform, unlike the Element Bio AVITI (from $5.6/Gb) or the MGI Tech G400, which depending on unofficial quotes can be at a similar range.
Read 4 tweets
Sep 29
Main headlines:
New NextSeq P4 flowcell with 500Gb output ($6/Gb still to be confirmed) in 2024, same instrument.
Nex NovaSeq X/X Plus instrument. 15Tb at $2/Gb, 20K WGS a year. Instrument is $1.25M. Image
Some comments:
If @UltimaGenomics can sell a $2-3M instrument at $1/Gb, then the new $ILMN Illumina NovaSeq X/XPlus instrument bridges half the gap to where the Ultima U100 aims to be in 2023.
The Infinity + NovaSeq X would make a long-read equivalent genome at $200x5 = $1000, which is in the ballpark of there $ONT.L Oxford @nanopore already is, and not far for the current (pending Oct update) $PACB PacBio Hifi equivalent.
Read 7 tweets
Sep 29
I'll be live tweeting the $ILMN Illumina #IGF with running commentary. I won't intend to be comprehensive with the slide deck screenshots, but cover the main headlines.
NovaSeq 6000 Dx, same as NovaSeq, but regulated FDA and CE (Europe). Image
6Tb in 44 hours, this hasn't changed ImageImage
Read 18 tweets
Sep 6
Chris Seymour at $ONT.L Oxford @nanopore tweets about Apple Silicon's AMX instruction set. A mysterious set of instructions now beginning to be mapped out by a group of volunteer developers. So what does Apple Silicon mean for #Bioinformatics?
As many will know, $AAPL Apple came up with their own silicon a few years ago, a branch off the @ARM 64-bit designs, of which they've been diverging ever since. The Apple M1 and M2 cores have been thoroughly reviewed in social media, but less from the optics of #Bioinformatics.
First of all, what reason did @Apple have to design their own silicon? Could they not just have adopted an @ARM design and stick to it? Well, the history of the company is full of examples of Apple wanting to do "their own thing" rather than integrating someone else's silicon...
Read 10 tweets
Sep 5
In #biotech #stocks news, no opening to the US market today due to Labor Day holiday, which is a perfect time to discuss the only stock in the list of #biotech companies that I track, which is not listed in the US stock market: $ONT.L Oxford @nanopore
ONT decided to IPO in the UK rather than the NASDAQ, with two main consequences to the stock price: (1) many of the retail broker apps with a US Dollar account won't trade it as easily as US stocks, and (2) the value of the stock will correlate with the value of GBP vs USD.
The later can be seen when looking at $ONT.L Oxford @nanopore stock versus the GBPUSD trend line (yellow): when the GBP loses value to the US Dollar, seemingly ONT loses value, being traded in GBP. And vice versa, for a large pharma company such as $AZN Astrazeneca ...
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(